Company Analysis

Revelation Biosciences, Inc. (REVB)

Nasdaq: REVB · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2020
Grade4.5
◀ Past 2.6● Present 3.7▶ Future 6.4
7 est.

Filings

318 filings since 2017 beside 71 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by May 15, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 36 days after the quarter ended. The proxy statement was last filed May 11, 2026.

Filings a yearinsider forms included
31537759596248
2020202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 3 times in the last 36 months, the newest Aug 19, 2026.Listing warning from its exchange (8-K item 3.01): 3 times in the last 36 months, the newest Jan 7, 2025.SEC letters: 24 in the last 36 months, the newest Feb 9, 2026.
Insider forms 71

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 5, 2026 8-K items 2.02, 9.01 Results released · Current report
Nov 5, 2026 10-Q Quarterly report Sep 30, 2026
Aug 19, 2026 8-K items 5.02, 9.01 Officer or director change · Current report Aug 17, 2026
Aug 14, 2026 SCHEDULE 13G/A Large holder update, amended
Aug 6, 2026 8-K items 2.02, 9.01 Results released · Current report
Aug 6, 2026 10-Q Quarterly report Jun 30, 2026
Jul 13, 2026 8-A12B Class of securities registered for listing
Jul 13, 2026 8-K items 1.01, 3.03, 5.03, 7.01, 9.01 Major agreement signed; Change to shareholders' rights; Charter, bylaw or fiscal-year change; Investor disclosure (Regulation FD) · Current report Jul 10, 2026
Jun 24, 2026 8-K items 5.02, 5.03, 5.07, 9.01 Officer or director change; Charter, bylaw or fiscal-year change; Shareholder vote · Current report
Jun 1, 2026 8-K items 8.01, 9.01 Other event · Current report
May 15, 2026 SCHEDULE 13G Large holder notice
May 11, 2026 ARS Annual report to shareholders
May 11, 2026 DEF 14A Proxy statement Jun 24, 2026
May 7, 2026 8-K items 2.02, 9.01 Results released · Current report
May 7, 2026 10-Q Quarterly report Mar 31, 2026
Apr 30, 2026 PRE 14A Preliminary proxy statement Jun 24, 2026
Apr 15, 2026 S-8 Employee stock plan registration
Mar 19, 2026 8-K items 3.03, 5.07, 9.01 Change to shareholders' rights; Shareholder vote · Current report Mar 18, 2026
Feb 26, 2026 8-K items 2.02, 9.01 Results released · Current report Nov 6, 2025
Feb 26, 2026 10-K Annual report Dec 31, 2025
Feb 17, 2026 DEF 14A Proxy statement Feb 14, 2026
Feb 17, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 11, 2026 EFFECT Registration effective
Feb 11, 2026 424B3 Shelf offering
Feb 9, 2026 CORRESP Reply to the SEC
Feb 6, 2026 PRE 14A Preliminary proxy statement
Feb 6, 2026 UPLOAD SEC comment letter
Jan 30, 2026 S-3 Shelf registration
Jan 29, 2026 8-K items 1.01, 3.02, 3.03, 9.01 Major agreement signed; Shares sold without registration; Change to shareholders' rights · Current report Jan 26, 2026
Jan 22, 2026 8-K items 8.01, 9.01 Other event · Current report Jan 21, 2026
Jan 20, 2026 SCHEDULE 13G Large holder notice
Dec 3, 2025 8-K items 3.03, 5.07, 8.01, 9.01 Change to shareholders' rights; Shareholder vote; Other event · Current report
Nov 14, 2025 SCHEDULE 13G Large holder notice
Nov 12, 2025 S-8 Employee stock plan registration
Nov 10, 2025 DEF 14A Proxy statement Dec 3, 2025
Nov 6, 2025 8-K items 2.02, 9.01 Results released · Current report
Nov 6, 2025 10-Q Quarterly report Sep 30, 2025
Oct 30, 2025 PRE 14A Preliminary proxy statement
Oct 29, 2025 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Oct 15, 2025 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
40 of 318 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton REVB · research, not advice